Activated T-Cell and Bispecific Antibody Immunotherapy for High-Risk Breast Cancer
Bench to BedsideLum L.G. · Sen M.
Roger Williams Cancer Center, Providence, R.I., and Blood Center of Southeast Wisconsin, Milwaukee, Wisc., USA
Nontoxic approaches are needed to improve overall survival (OS) and progression-free survival (PFS) for high-risk breast cancer. Combination immunotherapy (IT) consisting of activated T cells (ATC), interleukin-2 (IL-2), and CTL (GM-CSF) was given after peripheral blood stem cell transplant (PBSCT). There were no major toxicities and there appear to be improvements in OS and PFS over historical controls. In order to develop specific cytotoxic T lymphocytes (CTL), we combined ATC with the use of bispecific antibody (BiAb). By arming ATC with anti-CD3 × anti-HER2/neu BiAb (HER2BiAb), the approach converts nonspecific ATC into HER2/neu (HER2) specific CTL. ATC remain armed, kill tumor targets for days, and produce cytokines after binding to tumor. Arming ATC with BiAbs may prove to be effective for targeting a variety of tumors with and without high-dose chemotherapy.
Roger Williams Hospital, North Campus, Room G01
825 Chalkstone Avenue, Providence, RI 02908 (USA)
Tel. +1 401 456 2672, Fax +1 401 456 2398
Number of Print Pages : 7
Number of Figures : 5, Number of Tables : 0, Number of References : 27
Affiliated with Molecular Biology of Hematopoiesis Symposium
Vol. 105, No. 3, Year 2001 (Cover Date: Released July 2001)
Journal Editor: I. Ben-Bassat, Tel Hashomer
ISSN: 0001–5792 (print), 1421–9662 (Online)
For additional information: http://www.karger.com/journals/aha